HOME  >  Online journal

Vol.51 No.3 contents

Japanese/English

Full Text of PDF (279K) Article in Japanese

- Original Article -

Safety of Adjuvant Chemotherapy with Carboplatin and Weekly Paclitaxel for Pathological Stage IB-IIIB Non-small Cell Lung Cancer

Yoshio Okano¹, Hiroyuki Hino², Mitsuteru Yoshida², Nobuo Hatakeyama¹, Tsutomu Shinohara³, Fumitaka Ogushi^1
1Department of Respiratory Medicine, ²Department of Thoracic Surgery, ³Department of Clinical Investigation, National Hospital Organization, Kochi Hospital, Japan

---

Objective. The aim of this study was to determine the safety of combined therapy of carboplatin (CBDCA) and weekly paclitaxel (PTX) for postoperative pathological stage IB-IIIB non-small cell lung cancer (NSCLC), and to explore its usefulness. Patients and Methods. Postoperative NSCLC patients aged between 29 and 79 with a performance status of 0-1 were enrolled from 2003 April to 2008 October. CBDCA was administered on day 1, while PTX was administered on days 1, 8 and 15 during a therapy period of 28 days. The doses administered were all within the area under the curve (AUC) 5 for CBDCA and 60 mg/m² for PTX. Standard therapy was 4 courses. Toxicity was defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. We examined the toxicity and administration ratios of CBDCA and weekly PTX. Results. In all patients, G3-4 hematologic toxicities were detected as neutropenia in 8 cases (27.6%), anemia in 3 cases (10.3%), leukopenia in 2 cases (6.9%), thrombocytopenia in 1 case (3.4%), and febrile neutropenia in 1 case (3.4%). G3-4 non-hematologic toxicities were detected as hematemesis in 1 case (3.4%). There were no treatment-related deaths. We stopped the administration of PTX in 11 cases (3.4%), and the PTX delivery rate was 310/321 (96.6%). Conclusion. These results showed that the combination of CBDCA and weekly PTX had mild toxicity, and that this combination was effective is feasible and in patients with postoperative NSCLC.
key words: Weekly paclitaxel, Carboplatin, Adjuvant chemotherapy, Non-small cell lung cancer

Received: October 18, 2010
Accepted: March 4, 2011

JJLC 51 (3): 165-170, 2011